The venture was found in Europe in Belgium. The leading representative office of defined VC is situated in the Leuven.
Opposing the other organizations, this Gemma Frisius Fund works on 9 percentage points less the average amount of lead investments. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2018. Speaking about the real fund results, this VC is 5 percentage points less often commits exit comparing to other organizations. Deals in the range of 5 - 10 millions dollars are the general things for fund.
We can highlight the next thriving fund investment areas, such as Information Technology, Medical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Belgium. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Aristo Music Technology, TROD Medical, Cartagenia.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Gemma Frisius Fund, startups are often financed by Limburgse Reconversie Maatschappij, Vesalius Biocapital Partners, Quest for Growth. The meaningful sponsors for the fund in investment in the same round are PMV, Limburgse Reconversie Maatschappij, University of Leuven. In the next rounds fund is usually obtained by Flanders Innovation and Entrepreneurship (VLAIO), SmartFin Capital, PMV.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Augustine Therapeutics | $20M | 26 Jun 2024 | Ghent, East Flanders, Belgium | ||
Protealis | $25M | 23 Jan 2024 | - | ||
DName-iT | $685K | 30 Jun 2023 | Belfast, Northern Ireland, United Kingdom | ||
Dualyx | $47M | 15 May 2023 | Ghent, Oost-Vlaanderen, Belgium | ||
Rewind Therapeutics | 25 Jan 2023 | - | |||
AstriVax | $35M | 25 Aug 2022 | Heverlee, Vlaams-Brabant, Belgium | ||
Aphea.Bio | $21M | 14 Apr 2021 | Ghent, East Flanders, Belgium | ||
Aphea.Bio | $4M | 01 Apr 2021 | Ghent, East Flanders, Belgium | ||
Runeasi | $413K | 01 Nov 2020 | Leuven, Vlaams-Brabant, Belgium |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Augustine Therapeutics | $20M | 26 Jun 2024 | Ghent, East Flanders, Belgium | ||
Protealis | $25M | 23 Jan 2024 | - | ||
DName-iT | $685K | 30 Jun 2023 | Belfast, Northern Ireland, United Kingdom | ||
Dualyx | $47M | 15 May 2023 | Ghent, Oost-Vlaanderen, Belgium | ||
Rewind Therapeutics | 25 Jan 2023 | - | |||
AstriVax | $35M | 25 Aug 2022 | Heverlee, Vlaams-Brabant, Belgium | ||
Aphea.Bio | $21M | 14 Apr 2021 | Ghent, East Flanders, Belgium | ||
Aphea.Bio | $4M | 01 Apr 2021 | Ghent, East Flanders, Belgium | ||
Runeasi | $413K | 01 Nov 2020 | Leuven, Vlaams-Brabant, Belgium |